Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cortisone acetate
Drug ID BADD_D00533
Description Cortisone acetate was first isolate in 1935 and became more widely researched in 1949.[A226295] Since then, glucocorticoids such as cortisone acetate have been used to treat a number of inflammatory conditions such as endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, respiratory, hematologic, neoplastic, edematous, and gastrointestinal diseases and disorders.[A226300,L13203] Cortisone acetate was granted FDA approval on 13 June 1950.[L15107]
Indications and Usage For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders.
Marketing Status Prescription; Discontinued
ATC Code H02AB10; S01BA03
DrugBank ID DB01380
KEGG ID D00973
MeSH ID D003348
PubChem ID 5745
TTD Drug ID D0X4RS
NDC Product Code 0220-1554; 0143-1202; 0220-1553; 0143-9700; 64958-0025; 49452-2321; 0220-1550
Synonyms Cortisone | Cortisone Acetate | 17-Hydroxy-3,11,20-trioxopregn-4-en-21-yl acetate | Cortone Acetate | Adreson
Chemical Information
Molecular Formula C23H30O6
CAS Registry Number 50-04-4
SMILES CC(=O)OCC(=O)C1(CCC2C1(CC(=O)C3C2CCC4=CC(=O)CCC34C)C)O
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Alkalosis hypokalaemic14.01.02.002--Not Available
Angioedema10.01.05.009; 23.04.01.001--Not Available
Asthenia08.01.01.0010.010733%Not Available
Benign intracranial hypertension17.07.02.001--Not Available
Blood cortisol decreased13.10.09.0040.010733%Not Available
Carbohydrate tolerance decreased13.02.02.003--Not Available
Cardiac failure congestive02.05.01.002--Not Available
Cataract subcapsular06.06.01.002--Not Available
Confusional state17.02.03.005; 19.13.01.0010.010733%
Cough22.02.03.0010.010733%
Crohn's disease07.08.01.015; 10.02.01.0050.016100%Not Available
Depression19.15.01.0010.010733%
Dermatitis allergic10.01.03.014; 23.03.04.003--Not Available
Diabetes mellitus05.06.01.001; 14.06.01.001--Not Available
Diarrhoea07.02.01.0010.016100%
Drug hypersensitivity10.01.01.0010.096597%Not Available
Ecchymosis01.01.03.001; 23.06.01.001; 24.07.06.002--Not Available
Erythema23.03.06.0010.010733%Not Available
Euphoric mood19.04.02.0060.010733%
Exophthalmos05.02.02.002; 06.09.04.001--Not Available
Fluid retention14.05.06.002; 20.01.02.003--Not Available
Gait disturbance08.01.02.002; 17.02.05.0160.010733%
Gastrointestinal haemorrhage07.12.02.001; 24.07.02.0090.002800%Not Available
Haemoglobin decreased13.01.05.0030.010733%Not Available
Hallucination19.10.02.0020.016100%
Hallucination, auditory19.10.02.0030.010733%Not Available
Headache17.14.01.001--
Hirsutism05.05.01.005; 23.02.04.001--
Hyperhidrosis08.01.03.028; 23.02.03.004--
Hypertension24.08.02.0010.010733%
The 1th Page    1 2 3    Next   Last    Total 3 Pages